MedPath

Pazopanib

Generic Name
Pazopanib
Brand Names
Votrient
Drug Type
Small Molecule
Chemical Formula
C21H23N7O2S
CAS Number
444731-52-6
Unique Ingredient Identifier
7RN5DR86CK
Background

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions
Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Clinical Trials
Related News

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Phase 2
Recruiting
Conditions
Rhabdomyosarcoma, Recurrent, Refractory
Interventions
Drug: TGI chemotherapy
Drug: CIV chemotherapy
First Posted Date
2025-02-10
Last Posted Date
2025-02-10
Lead Sponsor
Shandong Cancer Hospital and Institute
Target Recruit Count
38
Registration Number
NCT06816771
Locations
🇨🇳

No. 440 Jiyan Road, Jinan City, Shandong Province, Jinan, Shandong, China

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Phase 2
Recruiting
Conditions
Solid Tumor
Precision Medicine
Interventions
Drug: Target Gene
Drug: Sacituzumab Govitecan-Hziy 180 MG
Drug: PD-1/PD-L1/PD-1&CTLA4 inhibitor
First Posted Date
2024-12-18
Last Posted Date
2024-12-18
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
300
Registration Number
NCT06739395
Locations
🇨🇳

Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Phase 3
Recruiting
Conditions
Sarcoma,Soft Tissue
Interventions
First Posted Date
2024-02-16
Last Posted Date
2025-04-09
Lead Sponsor
Intensity Therapeutics, Inc.
Target Recruit Count
333
Registration Number
NCT06263231
Locations
🇺🇸

Profound Research LLC, Farmington Hills, Michigan, United States

🇩🇪

Universitäres Krebszentrum (UCCL), Leipzig, Germany

🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 14 locations

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1
Recruiting
Conditions
Atypical Fibroxanthoma
Myoepithelioma
Fibrosarcoma NOS
Myxofibrosarcoma
Osteosarcoma, Extraskeletal
Adipocytic Neoplasm
Liposarcoma
Angiomatoid Fibrous Histiocytoma
Angiosarcoma
Interventions
Procedure: Surgical resection
Radiation: Proton beam radiation therapy
First Posted Date
2024-02-02
Last Posted Date
2025-04-25
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
139
Registration Number
NCT06239272
Locations
🇺🇸

Washington University Medical Center, Saint Louis, Missouri, United States

🇺🇸

Our Lady of the Lake Children's Hospital, Baton Rouge, Louisiana, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 1 locations

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

Phase 4
Not yet recruiting
Conditions
Thyroid Carcinoma
Renal Cell Carcinoma
Breast Carcinoma
Ovarian Carcinoma
Endometrium Carcinoma
Interventions
First Posted Date
2023-07-18
Last Posted Date
2023-11-29
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
30
Registration Number
NCT05949424
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Phase 2
Recruiting
Conditions
Soft Tissue Sarcoma
Interventions
First Posted Date
2023-01-11
Last Posted Date
2024-12-18
Lead Sponsor
Yonsei University
Target Recruit Count
116
Registration Number
NCT05679921
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Phase 2
Active, not recruiting
Conditions
Locally Advanced Uterine Corpus Leiomyosarcoma
Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Metastatic Uterine Corpus Leiomyosarcoma
Unresectable Uterine Corpus Leiomyosarcoma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Procedure: Transthoracic Echocardiography Test
First Posted Date
2022-06-27
Last Posted Date
2025-04-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
190
Registration Number
NCT05432791
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Alaska Women's Cancer Care, Anchorage, Alaska, United States

🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 142 locations

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Phase 1
Recruiting
Conditions
Advanced Soft-tissue Sarcoma
Metastatic Soft-tissue Sarcoma
Interventions
First Posted Date
2022-01-06
Last Posted Date
2024-04-08
Lead Sponsor
Centre Leon Berard
Target Recruit Count
58
Registration Number
NCT05180695
Locations
🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Institut Paoli-Calmettes, Marseille, France

🇫🇷

Institut Claudius Regaud, Toulouse, France

and more 2 locations

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Phase 3
Recruiting
Conditions
Sarcoma
Interventions
First Posted Date
2021-02-05
Last Posted Date
2023-08-30
Lead Sponsor
Centre Leon Berard
Target Recruit Count
96
Registration Number
NCT04741438
Locations
🇫🇷

Hôpital Jean Minjoz, Besançon, France

🇫🇷

CHU de Poitiers, Poitiers, France

🇫🇷

Centre Eugène Marquis, Rennes, France

and more 10 locations

Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb

Phase 2
Completed
Conditions
Metastatic Renal Cell Carcinoma
Interventions
First Posted Date
2020-07-08
Last Posted Date
2020-07-10
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Target Recruit Count
25
Registration Number
NCT04462445
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy